64Cu-DOTA-trastuzumab PET Imaging in Women with HER2 Overexpressing Breast Cancer
Abstract
The assessment of HER2 by immunohistochemical staining or fluorescence in situ hybridization (FISH) is performed on breast cancer tissue and is used to determine candidacy for trastuzumab therapy. The HER2 status in recurrent cancer has been shown to change after treatment of early stage disease. Generally, tissue sampling is limited to a single tumor site and may not be representative of all sites of metastasis. Functional imaging has the potential capacity to characterize whole-tumor HER2 status for all sites of disease. We previously synthesized to 111In-DTPA-trastuzumab and used it to image patients with HER2 positive breast cancer. We have recently synthesized 64Cu-DOTA-trastuzumab and tested it in model systems. Relative to the 111In-labeled antibody, positron emission tomography (PET) with 64Cu-DOTA-trastuzumab is superior in image quality with lower radiation absorbed doses to normal tissue. We have initiated a clinical trial of 64Cu-DOTA-trastuzumab PET in women with advanced HER2 positive breast cancer. To minimize uptake of the radiotracer in normal tissues, participants will receive one of 3 cold doses of trastuzumab to prior to 64Cu-DOTA-trastuzumab PET. After we have determined the optimal cold dose, women with metastatic disease having varying degrees of HER2 expression will undergo 64Cu-DOTA-trastuzumab PET. We hypothesize that PET imaging will accurately characterize tumor HER2 expression and thus identify patients who are likely to benefit from trastuzumab.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2011
- Accession Number
- ADA559942
Entities
People
- Andrew Raubitschek
- James Bading
- Joanne Mortimer
- Peter Conti